BRPI0614965A2 - método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit - Google Patents
método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kitInfo
- Publication number
- BRPI0614965A2 BRPI0614965A2 BRPI0614965A BRPI0614965A BRPI0614965A2 BR PI0614965 A2 BRPI0614965 A2 BR PI0614965A2 BR PI0614965 A BRPI0614965 A BR PI0614965A BR PI0614965 A BRPI0614965 A BR PI0614965A BR PI0614965 A2 BRPI0614965 A2 BR PI0614965A2
- Authority
- BR
- Brazil
- Prior art keywords
- taxane
- prodrug
- kit
- ester
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0517386A GB0517386D0 (en) | 2005-08-26 | 2005-08-26 | Combinations for the treatment of cancer |
GB0604114A GB0604114D0 (en) | 2006-03-02 | 2006-03-02 | Combinations for the treatment of cancer |
PCT/GB2006/003196 WO2007023302A1 (en) | 2005-08-26 | 2006-08-25 | Combinations comprising dmxaa for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0614965A2 true BRPI0614965A2 (pt) | 2016-09-13 |
Family
ID=37429252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0614965A BRPI0614965A2 (pt) | 2005-08-26 | 2006-08-25 | método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100297112A1 (pt) |
EP (1) | EP1917011A1 (pt) |
JP (1) | JP2009506019A (pt) |
KR (1) | KR20080047402A (pt) |
AU (1) | AU2006283371A1 (pt) |
BR (1) | BRPI0614965A2 (pt) |
CA (1) | CA2620436A1 (pt) |
EC (1) | ECSP088243A (pt) |
IL (1) | IL189376A0 (pt) |
MA (1) | MA29786B1 (pt) |
NO (1) | NO20080649L (pt) |
RU (1) | RU2404764C2 (pt) |
TN (1) | TNSN08056A1 (pt) |
WO (1) | WO2007023302A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001282717A1 (en) | 2000-07-28 | 2002-02-13 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
CA2708149A1 (en) * | 2007-12-13 | 2009-06-18 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
KR102216772B1 (ko) * | 2018-05-18 | 2021-02-17 | 주식회사 종근당 | 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655470A (en) * | 1969-03-29 | 1972-04-11 | Toa Gosei Chem Ind | Process for the production of a foamed thermoplastic resin sheet |
FR2516922A1 (fr) * | 1981-11-25 | 1983-05-27 | Lipha | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
IL77133A (en) * | 1984-12-04 | 1991-01-31 | Lilly Co Eli | Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation |
US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
US5620875A (en) * | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
EP0961617A4 (en) * | 1996-12-13 | 2002-08-07 | Lilly Co Eli | LEUKOTRINE ANTAGONISTS FOR TREATING FOCAL BRAIN CHEMISTRY |
US5910505A (en) * | 1997-03-21 | 1999-06-08 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
ES2234523T3 (es) * | 1999-03-01 | 2005-07-01 | Pfizer Products Inc. | Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos. |
AU5717400A (en) * | 1999-06-14 | 2001-01-02 | Cancer Research Ventures Limited | Cancer therapy |
US6806257B1 (en) * | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
EP1259237A4 (en) * | 2000-02-17 | 2004-07-28 | Merck & Co Inc | TREATMENT OR PREVENTION OF PROSTATE CANCER USING A SELECTIVE COX-2 INHIBITOR MEDICINE |
JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
AU2001282717A1 (en) * | 2000-07-28 | 2002-02-13 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
EP1620547B1 (en) * | 2003-04-21 | 2014-06-18 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
-
2006
- 2006-08-25 KR KR1020087006684A patent/KR20080047402A/ko not_active Application Discontinuation
- 2006-08-25 CA CA002620436A patent/CA2620436A1/en not_active Abandoned
- 2006-08-25 EP EP06779226A patent/EP1917011A1/en not_active Withdrawn
- 2006-08-25 JP JP2008527517A patent/JP2009506019A/ja active Pending
- 2006-08-25 RU RU2008111492/15A patent/RU2404764C2/ru not_active IP Right Cessation
- 2006-08-25 AU AU2006283371A patent/AU2006283371A1/en not_active Abandoned
- 2006-08-25 BR BRPI0614965A patent/BRPI0614965A2/pt not_active IP Right Cessation
- 2006-08-25 WO PCT/GB2006/003196 patent/WO2007023302A1/en active Application Filing
- 2006-08-25 US US12/064,633 patent/US20100297112A1/en not_active Abandoned
-
2008
- 2008-02-06 TN TNP2008000056A patent/TNSN08056A1/en unknown
- 2008-02-06 NO NO20080649A patent/NO20080649L/no not_active Application Discontinuation
- 2008-02-07 IL IL189376A patent/IL189376A0/en unknown
- 2008-03-05 EC EC2008008243A patent/ECSP088243A/es unknown
- 2008-03-17 MA MA30756A patent/MA29786B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
RU2404764C2 (ru) | 2010-11-27 |
WO2007023302A1 (en) | 2007-03-01 |
CA2620436A1 (en) | 2007-03-01 |
MA29786B1 (fr) | 2008-09-01 |
RU2008111492A (ru) | 2009-10-10 |
JP2009506019A (ja) | 2009-02-12 |
AU2006283371A1 (en) | 2007-03-01 |
TNSN08056A1 (en) | 2009-07-14 |
US20100297112A1 (en) | 2010-11-25 |
IL189376A0 (en) | 2008-06-05 |
EP1917011A1 (en) | 2008-05-07 |
NO20080649L (no) | 2008-05-26 |
ECSP088243A (es) | 2008-08-29 |
KR20080047402A (ko) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607545A2 (pt) | composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
BRPI0717907A2 (pt) | "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit" | |
BRPI0614965A2 (pt) | método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit | |
BRPI0516609A (pt) | composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto | |
BRPI0610359B8 (pt) | compostos de diaril-hidantoína, suas composições farmacêuticas e sais farmaceuticamente aceitáveis | |
BRPI0917540A2 (pt) | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável | |
DE602007002909D1 (de) | Geschoss zur verabreichung eines medikaments | |
WO2010078486A3 (en) | Opioid-containing oral pharmaceutical compositions and methods | |
BRPI0415288A (pt) | composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto | |
WO2007048064A3 (en) | Amino-pyrimidines as casein kinase ii (ck2) modulators | |
BR112012003578A2 (pt) | composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal. | |
BRPI0812877A2 (pt) | " compostos de piperazina, uso de um composto de piperazina, composição, e, método para combater vegetação indesejada ". | |
BRPI0611567A2 (pt) | composto e/ou sais farmaceuticamente aceitáveis dos mesmos, processo para síntese dos compostos, e formulação aerossol, e, uso de pelo menos uma pró-droga mútua de fenilfosfato | |
BRPI0821274A2 (pt) | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
BRPI0822033A2 (pt) | Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit | |
CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
BRPI0811816A2 (pt) | "forma de dosagem de picoplatina estabilizada, método para preparar uma forma de dosagem de picoplatina estabilizada, composições, kit, pluralidade de kits, método para tratamento de câncer e uso de uma quantidade eficaz da forma de dosagem" | |
BRPI0607775A2 (pt) | conjugado, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de doença | |
WO2005123049A3 (en) | A pharmaceutical composition for increasing the mitochondrial genesis | |
BRPI1013988A2 (pt) | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo | |
WO2009140341A3 (en) | Atorvastatin compositions | |
BRPI0917818A2 (pt) | composto, método para modular a atividade de ar, uso de composto, composição farmacêutica, e, para preparar um composto | |
WO2009102443A3 (en) | Octanoic acid formulations and methods of treatment using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 20080028595/RJ DE 27/02/2008. |
|
B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: ANTISOMA PLC (GB) |
|
B25A | Requested transfer of rights approved |
Owner name: ANTISOMA RESEARCH LIMITED (GB) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |